Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
Condition(s):Follicular Lymphoma; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma; Marginal Zone LymphomaLast Updated:July 11, 2019Completed
Hide Studies Not Open or Pending
Condition(s):Follicular Lymphoma; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma; Marginal Zone LymphomaLast Updated:July 11, 2019Completed
Condition(s):Human Papilloma VirusLast Updated:December 19, 2023Recruiting
Condition(s):Relapsed and/or Refractory Multiple MyelomaLast Updated:January 17, 2024Terminated
Condition(s):Acute Pain; Chronic PainLast Updated:December 30, 2015Completed
Condition(s):BRAF Mutant Metastatic MelanomaLast Updated:August 17, 2020Completed
Condition(s):Colorectal Cancer; Colonoscopy; Bowel Preparation SolutionLast Updated:March 20, 2024Completed
Condition(s):Opioid-Related DisordersLast Updated:September 26, 2023Recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:January 25, 2024Recruiting
Condition(s):Renal Cell CarcinomaLast Updated:December 23, 2021Completed
Condition(s):Tobacco Use TreatmentLast Updated:February 15, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.